Changes to NICE’s cost effectiveness thresholds take effect

2 April 2026 - NICE has implemented new measures to evaluate the cost effectiveness of medicines, following a policy change that ...

Read more →

NHS spending watchdog to review evidence on Alzheimer’s treatments

20 March 2026 - England’s drugs costs watchdog is to look again at whether new treatments for Alzheimer’s disease should ...

Read more →

Changes to NICE’s cost effectiveness thresholds confirmed

1 December 2025 - The Government has today announced that it will increase the thresholds NICE uses in evaluations of new ...

Read more →

Why the Government must urgently raise the NICE cost effectiveness threshold

7 October 2025 - NICE plays an important role in determining whether new medicines will be funded for NHS patients ...

Read more →

Britain prepares NHS drug spending hike to stave off Trump tariffs

8 October 2025 - The UK Government has drawn up proposals to increase the amount the National Health Service pays ...

Read more →

The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms

22 April 2025 - Real-world evidence is increasingly used and accepted by health technology assessment (HTA) bodies as supportive evidence ...

Read more →

Real-world evidence to support health technology assessment and payer decision making: is it now or never?

31 March 2025 - The aim of this policy article is twofold: (i) to provide a summary and update of recent ...

Read more →

What price is society willing to pay for new drugs?

12 December 2024 - The purpose of England's NHS is to improve the health and wellbeing of the nation through provision ...

Read more →

What is NICE’s severity modifier?

15 December 2024 - A guide to the severity modifier and how it is leading to more positive recommendations overall from ...

Read more →

Should NICE’s cost effectiveness thresholds change?

13 December 2024 - We explore the on-going debate around NICE’s cost effectiveness thresholds and what the future holds. ...

Read more →

Does NICE’s “severity modifier” for assessing diseases need to change?

22 November 2024 - Breast cancer charities and patients are “devastated” that the drug Enhertu will not be available in ...

Read more →

Prioritising patients in negotiations over drug pricing

14 April 2023 - Overpaying for medicines diverts funds away from other treatments and services. ...

Read more →

NICE’s new methods reflect society’s values

4 February 2023 - The mission of NICE is to get the best care to patients fast, while ensuring value for ...

Read more →

Can we use existing guidance to support the development of robust real world evidence for health technology assessment/payer decision-making?

2 November 2022 - Advances in the digitisation of health systems and expedited regulatory approvals of innovative treatments have led to ...

Read more →

Esketamine: NICE’s appraisal was unfair, appeal panel rules

8 September 2022 - The decision by the UK National Institute for Health and Care Excellence not to recommend esketamine ...

Read more →